Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2025
Effect of botulinum toxin injection on speech outcomes among patients with synkinetic facial nerve palsy: An assessment of speech intelligibility and quality of life.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lathif Adil, Charters Emma, Hussain Gazi, Ngo Quan, Low Tsu-Hui Hubert
Аннотация
BACKGROUND: Facial nerve palsy (FNP) considerably impairs functional outcomes and quality of life. For patients with synkinetic FNP, physiotherapy and botulinum toxin A (BTX) are commonly used to reduce hyperkinesis and improve facial expression. This study assessed the effect of BTX administration on oral competence in patients with FNP.
METHODS: Patients referred for BTX for management of their synkinetic FNP were recruited from the Sydney Facial Nerve Service. BTX was administered by a single surgeon. Their oral competence was measured using clinician and patient-rated outcome measures before and 4 weeks after BTX administration. This included a consonant analysis of a recorded reading sample, a subjective intelligibility rating by the clinician and patient, as well as 3 validated patient-reported questionnaires: the Speech Handicap Index (SHI), the Facial Disability Index (FDI), and the Oral Competence Questionnaire (OCQ).
RESULTS: Twenty participants were recruited for analysis. Patients were administered an average of 31.5 u of BTX on the ipsilateral side, and 9.25 u on the contralateral side. This resulted in statistically significant improvements in the percentage of correct consonants (p < 0.001), particularly post-alveolar/alveolar fricative sounds (s, z, and sh; p < 0.001). This corresponded with significantly better speech-related quality of life (SHI p = 0.003). There was no significant change in the OCQ or FDI scores.
CONCLUSIONS: BTX administration for patients with synkinetic FNP showed improved speech-related quality of life and speech intelligibility.
METHODS: Patients referred for BTX for management of their synkinetic FNP were recruited from the Sydney Facial Nerve Service. BTX was administered by a single surgeon. Their oral competence was measured using clinician and patient-rated outcome measures before and 4 weeks after BTX administration. This included a consonant analysis of a recorded reading sample, a subjective intelligibility rating by the clinician and patient, as well as 3 validated patient-reported questionnaires: the Speech Handicap Index (SHI), the Facial Disability Index (FDI), and the Oral Competence Questionnaire (OCQ).
RESULTS: Twenty participants were recruited for analysis. Patients were administered an average of 31.5 u of BTX on the ipsilateral side, and 9.25 u on the contralateral side. This resulted in statistically significant improvements in the percentage of correct consonants (p < 0.001), particularly post-alveolar/alveolar fricative sounds (s, z, and sh; p < 0.001). This corresponded with significantly better speech-related quality of life (SHI p = 0.003). There was no significant change in the OCQ or FDI scores.
CONCLUSIONS: BTX administration for patients with synkinetic FNP showed improved speech-related quality of life and speech intelligibility.